Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01805297 · ClinicalTrials.gov registry record · Phase 2
Aflibercept Injection for Proliferative Diabetic Retinopathy
A Phase 2 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01805297 is a Phase 2 study that has completed, run by University of Oklahoma. The registered enrollment target is 12 participants.
The verdict
NCT01805297, a Phase 2 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
Interventions
- DRUG Intravitreal Aflibercept Injection
- OTHER Standard Vitrectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01805297
The ClinicalTrials.gov registry entry for NCT01805297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intravitreal Aflibercept Injection is the first listed.
NCT01805297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01805297 about?
NCT01805297 is a clinical study titled "Aflibercept Injection for Proliferative Diabetic Retinopathy". To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
What is the current status of trial NCT01805297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01805297?
The interventions under investigation include: Intravitreal Aflibercept Injection (DRUG), Standard Vitrectomy (OTHER).
Who is sponsoring clinical trial NCT01805297?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.